Searched for
MOUNJARO DEAL
US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...- Boardroom on wheels: How MPVs have begun to speak a new language of luxury on Indian roadsThe growing popularity of the MPV among top executives and celebrities signals the arrival of a new trend -- one that is defined by practic...
- Mounjaro maker signs $2.7 billion deal on AI drug researchThe new deal builds on existing collaborations between the two companies, which struck a software licensing agreement in 2023, according to...
- Pfizer in diabetes drug deal with Sciwind BiosciencesPfizer has partnered with Sciwind Biosciences for a new type 2 diabetes drug. The deal could be worth up to 495 million dollars. This drug,...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Intense Lilly, Novo rivalry throws India weight-loss drug race wide openEli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...
- Take a pill! Novo Nordisk's Wegovy gets US' nod as daily pill for obesity treatmentNovo Nordisk's popular weight-loss drug Wegovy is now available as a pill in the US. The US Food and Drug Administration has approved the o...
- Eli Lilly cuts Zepbound price to widen access for obesity drugEli Lilly has reduced the cost of its popular obesity drug Zepbound for American patients. This move aims to make the treatment more access...
- What is Ozempic 2.0? Is it the future of weight loss? Here's what you need to know about the new drugA new pill, Orforglipron, is set to revolutionize weight loss and diabetes treatment. This daily pill, developed by Eli Lilly, has shown si...
- Eli Lilly becomes first drugmaker to hit trillion-dollar m-cap on weight-loss demand boomWall Street estimates the weight-loss drug market to be worth $150 billion by 2030, with Lilly and Novo together controlling the majority o...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Obesity drug Mounjaro becomes India's top-selling drug by value in OctoberEli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps...
- Pharma companies announce direct-to-consumer sales and price cuts in USSeveral pharmaceutical companies are now selling drugs directly to U.S. patients and offering significant discounts, responding to Presiden...
- European stocks rise as Novo Nordisk lifts healthcare on Wegovy dataShares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk o...
- Cipla eyes entry into India's weight management market amid rising demand and global competitionCipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...
- Novo Nordisk’s Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it worksNovo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy conta...
- What is 'Ozempic Feet'? The painful side effect of the controversial weight loss drug affecting celebritiesOzempic, a popular weight loss drug, may cause an unusual side effect. This effect is called 'Ozempic-feet'. It involves sagging skin on th...
- It's a gold for sponsors at Paris OlympicsOlympic sponsors saw a significant branding boost from the Paris Games after the Tokyo event's disruptions. The French capital attracted 11...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
- Weight loss drugs can wreak havoc on your face, warn expertsA drug overdose is bad news for your beauty.
Load More
